research Methodologic considerations in evaluating early clinical outcomes of GT20029 for androgenetic alopecia
GT20029 showed some hair growth improvement, but longer studies are needed for better results.
Search
for
Sort by
Research
30 / 1000+ resultsresearch Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
GT20029 helps regrow hair in men with hair loss and is well-tolerated.
research Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
Topical GT20029 effectively promotes hair regrowth and is well-tolerated.
research Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
Topical GT20029 effectively promotes hair regrowth and is well-tolerated for treating androgenetic alopecia.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
research Next Generation Therapeutics for Androgenetic Alopecia
A new treatment plan for hair loss combines targeted therapies and regenerative strategies to stabilize, reverse, and maintain hair growth.
research Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
Topical PROTACs show promise for treating skin conditions but need better stability and delivery methods.
research The 100 most cited articles in androgenetic alopecia: A bibliometric analysis
Recent research on androgenetic alopecia focuses on optimizing treatments, with promising new therapies emerging.
research Topical solutions for androgenetic alopecia: evaluating efficacy and safety
Topical treatments for hair loss can be effective but need careful safety evaluation.
research Emerging pharmacotherapies for Androgenetic Alopecia
New treatments for hair loss focus on targeting specific causes to improve effectiveness and safety.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
De nouvelles thérapies promettent de mieux traiter la perte de cheveux due à l'alopécie androgénétique.
research Updates in Treatment for Androgenetic Alopecia
New treatments for hair loss include low-dose oral minoxidil, light therapy, and innovative therapies targeting hair growth mechanisms.
research 안드로겐 탈모증 환자에서 HDMHG0401-10의 탈모방지, 양모 효과 및 안전성 평가를 위한 임상시험
research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
CG2001 is safe and well-tolerated for treating hair loss in men.
research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
CG2001 is safe and well-tolerated for treating hair loss, with fewer side effects than oral finasteride.
research Devices and genomic therapies
The document's conclusion cannot be provided because the document is not readable or understandable.
research Citalopram and finasteride with the lot number FI0510058-A have been voluntarily recalled by Greenstone, after a labelling error
research 10.1063/5.0132123.1
research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
CG2001 is safe, well-tolerated, and a promising treatment for hair loss with fewer side effects.
research “The Big One”, Toronto
The document's conclusion cannot be provided because the content is not available to parse.
research Finasteride 98319‐26‐7
research Report of Japanese Meeting, Tokyo, June 27, 1998
The document's content cannot be summarized because it is not accessible or understandable.
research Safety and efficacy of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial
The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
research MAGİSTRAL AVTOMOBİL YOLLARI. TARIXİ, TORPAQ SAHƏSİ, MÜASİR VƏZİYYƏTİ, PROBLEMLƏRİ
The document's conclusion cannot be provided because the content is not in a readable format.
research TBG096 stimulates hair regeneration through IGF-1R-mediated angiogenesis
research Development of validated methods for the simultaneous quantification of Finasteride and Tadalafil in newly launched FDA-approved therapeutic combination: greenness assessment using AGP, analytical eco-scale, and GAPI tools
The study developed accurate, precise, and environmentally friendly methods to measure Finasteride and Tadalafil in a new FDA-approved combination.
research Kin‐cohort analysis of LRRK2‐G2019S penetrance in Parkinson's disease
The LRRK2-G2019S mutation in Parkinson's disease has a lifetime penetrance of 25-35%, and finasteride may help reduce symptoms in adult male Tourette syndrome patients.
research 842Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS)
research Message from the Program Chair of the 2007 Annual Scientific Meeting
The document's content couldn't be processed.